WHO Pharmaceuticals Newsletter 2003, No. 04
(2003; 13 pages) View the PDF document
Table of Contents
Open this folder and view contentsREGULATORY MATTERS
Close this folderSAFETY OF MEDICINES
View the documentATYPICAL ANTI-PSYCHOTICS - Reports of hypertension
View the documentBOTULINUM A - Patients misled over safety
View the documentCHELIDONIUM MAJUS - Statement to advise use under supervision
View the documentCYCLO-OXYGENASE (COX)-2 INHIBITORS - Reports of hepatotoxicity
View the documentETONOGESTREL - Vaginal bleeding with sub-dermal implant
View the documentFLUTICASONE - ADR update
View the documentGATIFLOXACIN - Reports of abnormal glucose metabolism
View the documentHORMONE REPLACEMENT THERAPY (HRT) - ‘Million Women Study’ confirms breast cancer association
View the documentMEDROXY-PROGESTERONE - Reports of contraception failure with depot preparations
View the documentMEFLOQUINE - Patient guide warns of psychiatric adverse events
View the documentMETHOTREXATE - New solutions to prevent fatalities/adverse events
View the documentMINOCYCLINE - Hepatic reactions
View the documentPIPERACILLIN - Serum methotrexate monitoring advised during concomitant therapy
View the documentRIFAMPICIN & PYRAZINAMIDE - Warning against use in latent tuberculosis
View the documentSELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs): Reports of hyponatraemia
View the documentSIBUTRAMINE - Serotonin syndrome
View the documentTICLOPIDINE - No decrease in ADR reports
View the documentVIGA/VIGA FOR WOMEN - Presence of sildenafil
View the documentWARFARIN & MICONAZOLE - Reminder about interaction
Open this folder and view contentsDRUGS IN THE NEWS
 

SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs): Reports of hyponatraemia

Australia. The Adverse Drug Reactions Advisory Committee (ADRAC) has now received a total of 311 reports of hyponatraemia associated with the use of SSRIs and venlafaxine; in 67 of these reports the patient also had the syndrome of inappropriate antidiuretic hormone secretion. An SSRI was the only suspected drug in more than two-thirds of the 311 reports, although a small proportion (14%) of cases involved the concurrent use of a diuretic. The majority (75%) of patients were women and most (85%) were older than 60 years (mean age 77 years). Hyponatraemia usually occurred within the first 30 days of use and in many cases was the only abnormality reported, with a median serum sodium nadir of 120 mmol/L (range 113-133). Approximately two-thirds of cases recovered fully after withdrawal of the SSRI and fluid restriction, but three cases had a fatal outcome.

Reports in WHO-file: SSRIs: Hyponatraemia 2381

Reference:

Adverse Drug Reactions Advisory Committee (ADRAC).
Hyponatraemia with SSRIs. Australian Adverse Drug Reactions Bulletin 22: 10, Jun 2003.

to previous section to next section
 

Last updated: May 3, 2013